+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical safety data management in company non-sponsored trials



Clinical safety data management in company non-sponsored trials



Nihon Rinsho. Japanese Journal of Clinical Medicine 61(9): 1658-1665



There is currently no harmonized way in Japan to manage safety data which are obtained during clinical trials supported by Government funds. There are two types of clinical trials, 'sponsored trials(sponsored by industrial companies)' and 'non-sponsored trials(funded by the Government, etc.)'. The Japanese Ministry of Health and Welfare has issued many of pharmaceutical laws(GCP, GPMSP etc.) for the regulation of sponsored trials, while none has ever established for non-sponsored trials, thus leaving the most important quality control/assurance unregulated. In this manuscript we discuss that the simple application of pharmaceutical laws to government-sponsored trials can not be a proper answer because of the different nature of the two types of trials.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048555197

Download citation: RISBibTeXText

PMID: 14515738


Related references

Researchers raise concerns about secrecy in company-sponsored clinical trials. Chronicle of Higher Education 52(31): A29, 2006

Guidelines for monitoring company sponsored clinical trials in the pharmaceutical industry. Controlled Clinical Trials 12(5): 715-716, 1991

Withholding unfavourable results in drug company sponsored clinical trials. Lancet 1(8541): 1091, 1987

Data monitoring committees for multicenter clinical trials sponsored by the National Institutes of Health. I. Roles and membership of data monitoring committees for trials sponsored by the National Eye Institute. Controlled Clinical Trials 12(3): 424-437, 1991

Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe. Current Medical Research and Opinion 30(3): 395-405, 2014

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. Regulatory Toxicology and Pharmacology 70(1): 413-429, 2014

Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012. Current Medical Research and Opinion 31(7): 1431-1435, 2015

Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013. Current Medical Research and Opinion 33(3): 473-478, 2017

Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014. Current Medical Research and Opinion 34(7): 1239-1243, 2018

Data sharing, year 1--access to data from industry-sponsored clinical trials. New England Journal of Medicine 371(22): 2052-2054, 2014

Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. Journal of Clinical Oncology 25(32): 5070-5077, 2007

Pharmaceutical company-sponsored drug trials: what are we to believe?. Journal of Clinical Epidemiology 63(2): 126-127, 2010

Access to data from clinical trials sponsored by pharmaceutical companies. Addiction 102(5): 682-683, 2007

Pharmaceutical company-sponsored drug trials: the system is broken. Journal of Clinical Epidemiology 63(2): 128-129, 2010

Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials. Journal of the American Heart Association 5(4): E003307, 2016